The tweet was deleted by the author.
But we saved everything 🙂.
CVRx announced that Christus Trinity Mother Frances has reached its tenth successful Barostim implant for patients with heart failure.
This milestone highlights the dedication of Dr. Todd Bengtson, David McCaskill, NP, Emily Evans, NP, and their team in providing advanced therapy options. The Barostim neuromodulation treatment is designed to improve outcomes for individuals living with heart failure, signaling continued momentum in medical technology adoption.
CVRx recently added Michael Dale to its board to draw on his leadership experience in medical devices, according to a prior announcement from the company. The company is also advancing clinical integration of Barostim, hosting a symposium at AAHFN2026 to support adoption among advanced practice providers at a key industry event. These initiatives come as CVRx continues to expand the reach of its Barostim therapy.